Jason D. Smith

Insider Reports History

Location
Princeton, NJ
Signature
/s/ Jason D. Smith, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jason D. Smith:

Company Role Class Num Shares Value Price $ Report Date Ownership
UroGen Pharma Ltd. General Counsel Ordinary Shares 43,305 $827,558 $19.11 08 Sep 2025 Direct
UroGen Pharma Ltd. General Counsel Restricted Stock Units 3,334 07 Sep 2025 Direct

Insider Reports Filed by Jason D. Smith

Symbol Company Period Transactions Value $ Form Type Role Filing Time
URGN UroGen Pharma Ltd. 07 Sep 2025 3 -$29,047 4 General Counsel 09 Sep 2025, 18:32
URGN UroGen Pharma Ltd. 28 Jul 2025 2 -$143,971 4 General Counsel 30 Jul 2025, 16:03
URGN UroGen Pharma Ltd. 31 Jan 2025 10 -$82,202 4 General Counsel 04 Feb 2025, 11:51
URGN UroGen Pharma Ltd. 09 Sep 2024 3 -$19,895 4 General Counsel 12 Sep 2024, 13:51
URGN UroGen Pharma Ltd. 31 Jan 2024 3 -$78,790 4/A General Counsel 05 Feb 2024, 21:16
URGN UroGen Pharma Ltd. 31 Jan 2024 10 -$78,590 4 General Counsel 02 Feb 2024, 19:12
URGN UroGen Pharma Ltd. 07 Sep 2023 1 $0 4 General Counsel 08 Sep 2023, 15:41
URGN UroGen Pharma Ltd. 31 Aug 2023 3 -$68,438 4 General Counsel 05 Sep 2023, 16:28
URGN UroGen Pharma Ltd. 31 Jan 2023 8 -$16,556 4 General Counsel 02 Feb 2023, 12:04
URGN UroGen Pharma Ltd. 31 Aug 2022 3 -$25,999 4 General Counsel 02 Sep 2022, 11:40
URGN UroGen Pharma Ltd. 31 Jan 2022 5 -$3,138 4 General Counsel 02 Feb 2022, 15:35
URGN UroGen Pharma Ltd. 30 Nov 2021 3 -$45,750 4 General Counsel 02 Dec 2021, 12:16
URGN UroGen Pharma Ltd. 05 Jun 2021 1 $0 4 General Counsel 08 Jun 2021, 14:33
URGN UroGen Pharma Ltd. 17 May 2021 1 +$39,275 4 General Counsel 18 May 2021, 11:35